Elmind Capital’s Vaxcyte PCVX Stock Holding History

Elmind Capital’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.3M	Buy	452,340 +135,840	+43%	+$7.38M	6.61%	5
2026 Q1	$18.4M	Buy	316,500 +25,000	+9%	+$1.36M	5.22%	8
2025 Q4	$13.4M	Buy	+291,500	New	+$13M	3.97%	8

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Elmind Capital's PCVX Position: Q2 2026 in Review

Elmind Capital increased its Vaxcyte (PCVX) stake by 43% in Q2 2026, buying an estimated $7.38M and bringing the position to 452,340 shares worth $26.3M. The position accounts for 6.61% of the portfolio, ranked #5.

Elmind Capital first reported a position in PCVX in Q4 2025 and has held it in 3 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Elmind Capital held 452,340 shares of Vaxcyte worth $26.3M as of Q2 2026.
Elmind Capital bought 135,840 Vaxcyte shares in Q2 2026, an estimated $7.38M.
Vaxcyte made up 6.61% of Elmind Capital's portfolio in Q2 2026, its #5 holding.
Elmind Capital first reported a position in Vaxcyte in Q4 2025 and has held it in 3 quarters since.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.